Department of Dermatology

Measuring Dermatologic Diseases

Validated outcome measures have an important role in standardizing patient care and in developing reliable clinical trials by objectively measuring the severity of disease. The following tools have been developed by the Autoimmune Skin Disease Study Unit to assess cutaneous disease activity and damage in autoimmune skin diseases.

  • Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI™)
    • The CLASI™ is a validated, quantitative outcome measure for disease activity and severity in cutaneous lupus erythematosus (CLE). Used for clinical trials and assessment of clinical outcomes in clinical settings. An educational slide series for training on how to use the CLASI™ tool is available.
  • Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI™)
    • The CDASI™ is a validated, quantitative outcome measure for disease activity and severity in cutaneous dermatomyositis. Used for clinical trials and assessment of clinical outcomes in clinical settings. An educational slide series for training on how to use the CDASI™ tool is available.
  • Pemphigus Disease Area Index (PDAI)
    • The PDAI is a validated scoring system for evaluating pemphigus disease severity. Used for clinical trials and assessment of clinical outcomes in clinical settings.
  • Bullous Pemphigoid Disease Area Index (BPDAI)
    • The BPDAI is a scoring system for evaluating pemphigoid disease severity. Used for clinical trials and assessment of clinical outcomes in clinical settings.

The tools and teaching slides are available for licensing for pharmaceutical sponsored clinical trials or for academic/clinical use by contacting the Penn Center for Innovation at 215-573-4307 or email shilpabh@upenn.edu. We will register you as a licensee and will provide the CLASI tool as a form.

Share This Page: